E3 Diabetes Program for Type 2 Diabetes
(E3Diabetes Trial)
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What data supports the effectiveness of the E3 Multidisciplinary Team and E3 Self-Guided Type 2 Diabetes Education treatment for Type 2 Diabetes?
Research shows that programs involving multidisciplinary teams and self-management education can help people with Type 2 diabetes better control their blood sugar levels and improve their quality of life. These approaches often involve healthcare professionals like nurses and dietitians working together to provide education and support.12345
Is the E3 Diabetes Program for Type 2 Diabetes safe for humans?
The available research on diabetes education programs, including multidisciplinary and self-management education, generally shows improvements in health outcomes without significant safety concerns. However, specific safety data for the E3 Diabetes Program itself is not detailed in the provided studies.16789
How does the E3 Diabetes Program treatment differ from other treatments for type 2 diabetes?
The E3 Diabetes Program is unique because it uses a multidisciplinary team approach combined with self-guided education to help patients manage type 2 diabetes. This approach emphasizes comprehensive lifestyle changes and education, involving various healthcare professionals to support patients in achieving better control of their condition and preventing complications.110111213
What is the purpose of this trial?
This study aims to decrease the racial gap in type 2 diabetes control in African American and Latinx patients in Rush University Medical Center clinics.
Eligibility Criteria
This trial is for African American and Latinx adults with uncontrolled Type 2 Diabetes (A1C level of 8.0 or higher in the past 3 months), who are patients at eligible Rush primary care clinics, have access to a cellphone, and are not enrolled in other remote diabetes programs.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive remote glucose monitoring, medication titration, and dietary education for 6 months
Follow-up
Participants are monitored for changes in glycemic control and other health outcomes
Long-term Follow-up
A1C levels are measured to check for persistence in improvement
Treatment Details
Interventions
- E3 Multidisciplinary Team
- E3 Self-Guided Type 2 Diabetes Education
Find a Clinic Near You
Who Is Running the Clinical Trial?
Rush University Medical Center
Lead Sponsor
Novartis Pharmaceuticals
Industry Sponsor
Dr. Vas Narasimhan
Novartis Pharmaceuticals
Chief Executive Officer since 2018
MD from Harvard Medical School
Dr. Shreeram Aradhye
Novartis Pharmaceuticals
Chief Medical Officer since 2021
MD